文献速递肾癌与肾肿瘤膀胱癌与上尿路尿路上皮癌前列腺癌

高通量基因组分析时代泌尿系统肿瘤的遗传图谱及其临床意义

The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis.
PubMed 文献 · BJU Int · 2020-05-22

本文综述TCGA等大型项目对肾细胞癌、肌层浸润性膀胱癌、前列腺癌和睾丸生殖细胞肿瘤的分子表征,重点总结具有特征性遗传改变和不同预后的分子亚型,以及免疫检查点抑制、表观遗传治疗和靶向MAPK、PI3K及DNA修复通路的新兴治疗选项。

要点

  • 四种泌尿系统肿瘤的分子表征已取得重大进展,鉴定出具有特征性遗传改变和不同预后的分子亚型。
  • 表观遗传学和microRNA相关的预后改变也被识别。
  • 免疫检查点抑制、表观遗传治疗及靶向MAPK、PI3K和DNA修复通路的药物正在研究中。

核心结论

  • 理解特定遗传改变如何影响预后是实现个体化预后和高度靶向治疗的关键,TCGA等大型联盟的工作正逐步实现这些目标。

研究设计与样本

  • 叙述性综述,总结TCGA及其他主要研究的数据,聚焦肾细胞癌、肌层浸润性膀胱癌/癌、前列腺癌和睾丸生殖细胞肿瘤四种泌尿系统肿瘤。

主要发现

  • 四种泌尿系统肿瘤的分子表征取得重大进展,近期研究聚焦于鉴定具有特征性遗传改变和不同预后的分子亚型。
  • 其他预后改变包括表观遗传学和microRNA相关的改变。
  • 治疗方面涌现多种选择,包括免疫检查点抑制、表观遗传治疗以及靶向MAPK、PI3K和DNA修复通路的药物。
  • 大量试验正在进行以研究这些新药的效应。

临床怎么用

  • 为患者提供个体化预后需理解特定遗传改变对预后的影响。
  • 针对患者肿瘤特定遗传背景提供高度靶向治疗至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: With the advent of high-throughput genome analysis, we are increasingly able to sequence and hence understand the pathogenic processes underlying individual cancers. Recently, consortiums such as The Cancer Genome Atlas (TCGA) have performed large-scale projects to this end, providing significant amounts of information regarding the genetic landscapes of several cancers. PATIENTS AND METHODS: We performed a narrative review of studies from the TCGA and other major studies. We aimed to summarise data exploring the clinical implications of specific genetic alterations, both prognostically and therapeutically, in four major urological cancers. These were renal cell carcinoma, muscle-invasive bladder cancer/carcinoma, prostate cancer, and testicular germ cell tumours. RESULTS: With these four urological cancers, great strides have been made in the molecular characterisation of tumours. In particular, recent studies have focussed on identifying molecular subtypes of tumours with characteristic genetic alterations and differing prognoses. Other prognostic alterations have also recently been identified, including those pertaining to epigenetics and microRNAs. In regard to treatment, numerous options are emerging for patients with these cancers such as including immune checkpoint inhibition, epigenetic-based treatments, and agents targeting MAPK, PI3K, and DNA repair pathways. There are a multitude of trials underway investigating the effects of these novel agents, the results of which are eagerly awaited. CONCLUSIONS: As medicine chases the era of personalised care, it is becoming increasingly important to provide individualised prognoses for patients. Understanding how specific genetic alterations affects prognosis is key for this. It will also be crucial to provide highly targeted treatments against the specific genetics of a patient's tumour. With work performed by the TCGA and other large consortiums, these aims are gradually being achieved. Our review provides a succinct overview of this exciting field that may underpin personalised medicine in urological oncology.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Light A, Ahmed A, Dasgupta P, et al. The genetic landscapes of urological cancers and their clinical implications in the era of high-throughput genome analysis. BJU Int. 2020. PMID: 32306543. doi:10.1111/bju.15084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。